Zydus Lifesciences: From Gujarat to Global, Now FDA-Approved for World Domination?
1. At a Glance
Zydus isn’t just a “Cadila rebranded” story — it’s ₹98,000 Cr of pure pharma muscle. With FY25 net profit of ₹4,673 Cr and ROE north of 21%, this one’s dosing investors with compounding.
2. Introduction with Hook
What if a Gujarati pharma company grew its profit 5x since COVID and still managed to keep its name off Twitter scandals? That’s Zydus.
Market Cap: ₹98,380 Cr
FY25 Revenue: ₹23,242 Cr
FY25 PAT: ₹4,673 Cr
ROE: 21.3%
OPM: 30% (a margin that would make even Apple jealous)
The FDA loves them. Investors… are finally catching on.
3. Business Model (WTF Do They Even Do?)
Core Segments:
Generic Formulations (US + India)
Specialty Drugs
APIs (Active Pharma Ingredients)
Biologics & Vaccines
Animal Healthcare (Zydus Animal Health spin-off happened earlier)
